Abstract：Objective To compare the clinical effect of Febuxostat and Allopurinol in the treatment of chronic kidney disease (CKD) combined with hyperuricemia (HUA). Methods A total of 60 patients with CKD (stage 2-4) combined with HUA who were treated in our hospital from January 2017 to May 2019 were selected as research subjects. They were randomly divided into observation group (n=30) and control group (n=30) based on odd/even number. On the basis of routine treatment, patients in the observation group were treated with Febuxostat to reduce uric acid, and in the control group, patients were treated with Allopurinol to reduce uric acid. The treatment lasted for six months. The levels of blood uric acid, serum creatinine, blood urea nitrogen and the glomerular filtration rate (eGFR) before and after treatment were compared in the two groups. The total effective rate of treatment, incidence rates of eGFR decrease＞10%and adverse reaction were compared between the two groups. Results The total effective rate of treatment in the observation group was higher than that in the control group, and the difference was statistically significant (P＜0.05). The incidence rate of eGFR decrease＞10% of patients in the observation group was lower than that in the control group, and the difference was statistically significant (P＜0.05).The levels of blood uric acid,serum creatinine and blood urea nitrogen of the two groups after treatment were lower than those of their respective group before treatment, and the differences were statistically significant(P＜0.05).After treatment,the levels of blood uric acid,serum creatinine and blood urea nitrogen in the observation group were lower than those in the control group, with statistically significant differences(P＜0.05). There was no statistically significant difference in eGFR between the two groups after treatment (P＞0.05).There was no statistically significant difference in the total incidence rate of adverse reactions between the two groups(P＞0.05). Conclusion Both Febuxostat and Allopurinol can effectively treat patients with mild or moderate renal insufficiency combined with HUA. They can markedly reduce blood uric acid levels and improve renal function. The clinical effect of Febuxostat is more obvious than that of Allopurinol. No serious adverse reactions occur in either group.
张青； 彭卫平； 杨文早. 非布司他与别嘌醇治疗慢性肾脏病伴高尿酸血症的临床效果比较[J]. 中国当代医药, 2020, 27(16): 98-101.
ZHANG Qing； PENG Wei-ping； YANG Wen-zao. Clinical effect comparison of Febuxostat and Allopurinol in the treatment of chronic kidney diseases combined with hyperuricemia. 中国当代医药, 2020, 27(16): 98-101.
Miao Y，Ottenbros SA，Laverman GD，et al.Effect of a reduction in uric acid on renal outcomes during losartan treatment:a posthoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the AngiotensinⅡAntagonist Losartan Trial[J].Hypertension，2011，58（1）：2-7.
[2]
FDA.ULORIC（febuxostat）tablet for oral use[EB/OL].http：//www.accessdata.fda.gov/drugsatfda-docs/label/2009/021856l bl.pdf.
Hosoya T，Ohno I.A repeated oral administration study of febuxostat （TMX-67），a non-purine-selective inhibitor of xanthine oxidase，in patientswith impaired renal function in Japan：pharmacokinetic and pharmacodynamic study[J].J Clin Rheumatol，2011，17（4 Suppl 2）：S27-S34.
京公网安备 11010502046607号